Versant Capital Management’s Travere Therapeutics TVTX Stock Holding History

Versant Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.7K	Hold	611	–	–	﹤0.01%	1620
2026 Q1	$18.2K	Buy	611 +41	+7%	+$1.23K	﹤0.01%	1865
2025 Q4	$21.8K	Hold	570	–	–	﹤0.01%	1585
2025 Q3	$13.6K	Buy	570 +8	+1%	+$150	﹤0.01%	1786
2025 Q2	$8.32K	Sell	562 -28	-5%	-$464	﹤0.01%	1970
2025 Q1	$10.6K	Hold	590	–	–	﹤0.01%	1703
2024 Q4	$10.3K	Buy	+590	New	+$10.4K	﹤0.01%	1378
2024 Q2	–	Sell	-61	Closed	-$470	–	2010
2024 Q1	$470	Buy	+61	New	+$515	﹤0.01%	1709
2023 Q3	–	Sell	-9	Closed	-$138	–	2058
2023 Q2	$138	Buy	+9	New	+$164	﹤0.01%	2019

Other funds holding TVTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

HCMT

Highland Capital Management (Tennessee) Memphis, Tennessee $2.17B AUM 54.74% 1-Year Est. Return

Versant Capital Management's TVTX Position: Q2 2026 in Review

Versant Capital Management held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 611 shares worth $34.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1620.

Versant Capital Management first reported a position in TVTX in Q2 2023 and has held it in 9 quarters since. 35 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Versant Capital Management held 611 shares of Travere Therapeutics worth $34.7K as of Q2 2026.
Versant Capital Management left its Travere Therapeutics share count unchanged in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1620 holding.
Versant Capital Management first reported a position in Travere Therapeutics in Q2 2023 and has held it in 9 quarters since.
35 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.